search
Back to results

Denosumab In Addition To Intense Urate-Lowering Therapy for Bone Erosions

Primary Purpose

Gout

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Denosumab
Sponsored by
University of Alabama at Birmingham
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Gout

Eligibility Criteria

30 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age 30 years or older and able to provide informed consent
  • Diagnosis of gout according to the American College of Rheumatology (ACR) / European League Against Rheumatism (EULAR) classification criteria
  • Radiographic foot bone erosion attributable to gout and confirmed by a radiologist
  • Serum urate of ≤ 5 mg/dL (300 µmol/L) or less*

Exclusion Criteria:

  • Treatment with bisphosphonates in the preceding 2 years
  • Any prior treatment with denosumab
  • Women of childbearing potential, who are not currently using birth control, are pregnant, planning to become pregnant, or are breast-feeding
  • Men planning to conceive in the next 12 months
  • Unstable systemic medical condition
  • Uncontrolled hyperthyroidism
  • Uncontrolled hypothyroidism
  • History of Addison disease
  • History of osteomalacia
  • History of osteonecrosis of the jaw (ONJ)
  • History of atypical femur fracture
  • History of tooth extraction, jaw surgery, dental implants, or other dental surgery within the prior 6 months
  • History of anorexia nervosa, bulimia (by history or physical) or obvious malnutrition.
  • Invasive dental work planned in the next 2 years
  • History of Paget's disease of bone
  • Other bone diseases which affect bone metabolism
  • Vitamin D deficiency [25(OH) vitamin D level < 20 ng/mL (<49.9 nmol/L)]†
  • Hypercalcemia
  • Elevated transaminases ≥ 2.0 x upper limit of normal (ULN)
  • Elevated total bilirubin > 1.5x ULN
  • History of any solid organ or bone marrow transplant
  • Malignancy within the last 5 years (except cervical carcinoma in situ or basal cell carcinoma)
  • Hypocalcemia
  • Poorly tolerant of ULT including allopurinol, febuxostat, or probenecid
  • Estimated glomerular filtration rate < 30 mL/minute/1.73 m^2
  • Current use of any biological therapy (eg. infliximab, etanercept, adalimumab, etc.)
  • Treatment history with pegloticase or another recombinant uricase
  • Recipient of an investigational drug within 4 weeks prior to study drug administration or plans to take an investigational agent during the study

Sites / Locations

  • University of Alabama at Birmingham

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

No Intervention

Arm Label

Intervention

Control

Arm Description

Denosumab 60 mg administered subcutaneously (SC) every 6 months for a year + urate lowering therapy (ULT) standard of care

Standard urate lowering therapy

Outcomes

Primary Outcome Measures

CT Bone Erosion Score
Change in the foot CT bone erosion score from baseline to 12 months. A total of 14 bones of the foot are scored. Each bone of the scored separately on a scale from 0 to 10, based on the proportion of eroded bone compared with the 'assessed bone volume', judged on all available images-0: no erosion; 1: 1-10% of bone eroded; 2: 11-20% bone eroded; 3:21-30% of bone eroded; 4: 31-40% of bone eroded; 5: 51-60% bone eroded; 7:61-70% of bone eroded; 8: 71-80% of bone eroded; 9: 81-90% bone eroded; 10:>=91% of bone eroded. Higher score indicates worsening of erosion. Score ranges from 0 to 140.

Secondary Outcome Measures

Decrease in Bone Reabsorption
Change in bone reabsorption as measured by serum carboxy-terminal collagen crosslinks (CTX) levels (pg/mL) over 12 months. Lower values represent varying degrees of suppression of normal bone turnover. The reference ranges for C-terminal telopeptide in serum are as follows: Female (premenopausal): 40-465 pg/mL Female (postmenopausal): 104-1008 pg/mL Male: 60-700 pg/mL
Change in Subject Reported Functional Status (Disability)
Change in subject reported functional status (disability) by Health Assessment Questionnaire (HAQ) will be assessed from baseline over 12 months. 0 to 1 are generally considered to represent mild to moderate difficulty, 1 to 2 moderate to severe disability, and 2 to 3 severe to very severe disability.
Subject Reported Change in Physical Health
Subject reported change in physical and mental health by Short Form Health Survey (SF-12) scores assessed from baseline over 12 months. Range 0-100 with higher scores representing better self-reported health.
Subject Reported Change in Mental Health
Subject Reported Change in Mental Health on SF-12 mental component form. Range 0-100 with higher scores representing better self-reported health
Assessment of Pain
Assessment of pain score by visual analogue scale (VAS) reported from baseline over 12 months. Range 0-10 with higher scores representing more pain.

Full Information

First Posted
September 13, 2016
Last Updated
October 22, 2021
Sponsor
University of Alabama at Birmingham
Collaborators
University of Auckland, New Zealand
search

1. Study Identification

Unique Protocol Identification Number
NCT02903446
Brief Title
Denosumab In Addition To Intense Urate-Lowering Therapy for Bone Erosions
Official Title
Denosumab In Addition To Intense Urate-Lowering Therapy for Bone Erosions in Gout: A Pilot Study
Study Type
Interventional

2. Study Status

Record Verification Date
October 2021
Overall Recruitment Status
Completed
Study Start Date
February 1, 2017 (Actual)
Primary Completion Date
March 1, 2020 (Actual)
Study Completion Date
March 1, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Alabama at Birmingham
Collaborators
University of Auckland, New Zealand

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Bone erosions are a common manifestation and feature of structural damage in severe/chronic tophaceous gout. Management of this destructive and often debilitating gout complication has focused exclusively on urate-lowering therapy (ULT) to reduce frequency of gout attacks, but little attention has been given to prevention or reversal of gout related bone erosions and other structural damage to bone caused by gout. Since there is no known effective treatment to attenuate or improve structural damage caused by gout, we propose a pilot, controlled, proof-of-concept study in which denosumab, an FDA approved medication for the treatment of bone loss, will be added to standard ULT in 20 patients with erosive gout.
Detailed Description
A recently published clinical trial with zoledronic acid failed to show an effect in improving bone erosions among individuals with chronic tophaceous gout, despite improvements in bone mineral density (BMD) and bone turnover markers. However, it is known that increased numbers of osteoclasts (cells that absorb bone tissue during growth and healing) in patients with tophaceous gout are most likely a result of enhanced osteoclast activity as these patients also have higher circulating levels of the protein receptor activator of nuclear factor kappa-B ligand (RANKL). RANKL has been identified to affect the immune system and control bone regeneration and remodeling. Furthermore, peripheral blood cells and synovial fluid cells taken from patients with erosive gout preferentially formed osteoclast-like cells in the presence of RANKL. The number of osteoclasts formed significantly correlates with the number of tophi in gout patients. Denosumab (Prolia®) is a fully human monoclonal antibody with a high affinity for RANKL that can bind and neutralize the activity of human RANKL. Given the relevance of RANKL in the mechanism of gouty erosions,a central hypothesis of this pilot study is that denosumab is more likely to precisely target RANKL and the mechanism of gouty erosions than zoledronic acid.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gout

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
20 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Intervention
Arm Type
Active Comparator
Arm Description
Denosumab 60 mg administered subcutaneously (SC) every 6 months for a year + urate lowering therapy (ULT) standard of care
Arm Title
Control
Arm Type
No Intervention
Arm Description
Standard urate lowering therapy
Intervention Type
Drug
Intervention Name(s)
Denosumab
Other Intervention Name(s)
Prolia
Intervention Description
Participants will be randomized (1:1) allocation to denosumab 60 mg administered subcutaneously (SC) every 6 months for a year + ULT standard of care OR ULT standard of care therapy
Primary Outcome Measure Information:
Title
CT Bone Erosion Score
Description
Change in the foot CT bone erosion score from baseline to 12 months. A total of 14 bones of the foot are scored. Each bone of the scored separately on a scale from 0 to 10, based on the proportion of eroded bone compared with the 'assessed bone volume', judged on all available images-0: no erosion; 1: 1-10% of bone eroded; 2: 11-20% bone eroded; 3:21-30% of bone eroded; 4: 31-40% of bone eroded; 5: 51-60% bone eroded; 7:61-70% of bone eroded; 8: 71-80% of bone eroded; 9: 81-90% bone eroded; 10:>=91% of bone eroded. Higher score indicates worsening of erosion. Score ranges from 0 to 140.
Time Frame
Baseline, 12 months
Secondary Outcome Measure Information:
Title
Decrease in Bone Reabsorption
Description
Change in bone reabsorption as measured by serum carboxy-terminal collagen crosslinks (CTX) levels (pg/mL) over 12 months. Lower values represent varying degrees of suppression of normal bone turnover. The reference ranges for C-terminal telopeptide in serum are as follows: Female (premenopausal): 40-465 pg/mL Female (postmenopausal): 104-1008 pg/mL Male: 60-700 pg/mL
Time Frame
Baseline, 12 months
Title
Change in Subject Reported Functional Status (Disability)
Description
Change in subject reported functional status (disability) by Health Assessment Questionnaire (HAQ) will be assessed from baseline over 12 months. 0 to 1 are generally considered to represent mild to moderate difficulty, 1 to 2 moderate to severe disability, and 2 to 3 severe to very severe disability.
Time Frame
Baseline, 12 months
Title
Subject Reported Change in Physical Health
Description
Subject reported change in physical and mental health by Short Form Health Survey (SF-12) scores assessed from baseline over 12 months. Range 0-100 with higher scores representing better self-reported health.
Time Frame
Baseline, 12 months
Title
Subject Reported Change in Mental Health
Description
Subject Reported Change in Mental Health on SF-12 mental component form. Range 0-100 with higher scores representing better self-reported health
Time Frame
Baseline, 12 months
Title
Assessment of Pain
Description
Assessment of pain score by visual analogue scale (VAS) reported from baseline over 12 months. Range 0-10 with higher scores representing more pain.
Time Frame
Baseline, 12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
30 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age 30 years or older and able to provide informed consent Diagnosis of gout according to the American College of Rheumatology (ACR) / European League Against Rheumatism (EULAR) classification criteria Radiographic foot bone erosion attributable to gout and confirmed by a radiologist Serum urate of ≤ 5 mg/dL (300 µmol/L) or less* Exclusion Criteria: Treatment with bisphosphonates in the preceding 2 years Any prior treatment with denosumab Women of childbearing potential, who are not currently using birth control, are pregnant, planning to become pregnant, or are breast-feeding Men planning to conceive in the next 12 months Unstable systemic medical condition Uncontrolled hyperthyroidism Uncontrolled hypothyroidism History of Addison disease History of osteomalacia History of osteonecrosis of the jaw (ONJ) History of atypical femur fracture History of tooth extraction, jaw surgery, dental implants, or other dental surgery within the prior 6 months History of anorexia nervosa, bulimia (by history or physical) or obvious malnutrition. Invasive dental work planned in the next 2 years History of Paget's disease of bone Other bone diseases which affect bone metabolism Vitamin D deficiency [25(OH) vitamin D level < 20 ng/mL (<49.9 nmol/L)]† Hypercalcemia Elevated transaminases ≥ 2.0 x upper limit of normal (ULN) Elevated total bilirubin > 1.5x ULN History of any solid organ or bone marrow transplant Malignancy within the last 5 years (except cervical carcinoma in situ or basal cell carcinoma) Hypocalcemia Poorly tolerant of ULT including allopurinol, febuxostat, or probenecid Estimated glomerular filtration rate < 30 mL/minute/1.73 m^2 Current use of any biological therapy (eg. infliximab, etanercept, adalimumab, etc.) Treatment history with pegloticase or another recombinant uricase Recipient of an investigational drug within 4 weeks prior to study drug administration or plans to take an investigational agent during the study
Facility Information:
Facility Name
University of Alabama at Birmingham
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35294
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Denosumab In Addition To Intense Urate-Lowering Therapy for Bone Erosions

We'll reach out to this number within 24 hrs